Trial Profile

Phase 2 Study of Bevacizumab in Combination with Alternating XELIRI and XELOX As First-line Treatment of Patients with Metastatic Colorectal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Capecitabine; Irinotecan; Oxaliplatin
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms AXOAXI

Most Recent Events

24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
27 Jul 2020 Status changed from recruiting to active, no longer recruiting.
04 Jul 2020 Primary endpoint (Resection eligibility rate (Resectability rate)) has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com